SciTrends
SciTrends is a cutting-edge platform dedicated to keeping professionals, researchers, and enthusiasts abreast of the latest developments in the scientific realm. Focused on biological, chemical, physical, life sciences, engineering, and technology, Sci-Trends serves as a centralized hub for accessing timely and relevant information from diverse scientific disciplines.
-
A global phase 3 study of serplulimab plus chemotherapy as first-line treatment for advanced squamous non-small-cell lung cancer (ASTRUM-004)
A recent study shows that First-line serplulimab plus chemotherapy improves PFS and OS and promises another treatment option for these patients. Their results demonstrate that adding serplulimab to chemotherapy significantly improves survival in advanced squamous NSCLC patients, with manageable safety.
-
Interferon-stimulated neutrophils as a predictor of immunotherapy response
Researchers indentified interferon-stimulated, Ly6Ehi neutrophils as a blood-borne biomarker of anti-PD1 response in mice at baseline. Ly6Ehi neutrophils are induced by tumor-intrinsic activation of the STING (stimulator of interferon genes) signaling pathway and possess the ability to directly sensitize otherwise non-responsive tumors to anti-PD1 therapy, in part through IL12b-dependent activation of cytotoxic T cells. By translating their pre-clinical findings to a cohort of patients with non-small cell lung cancer and melanoma (n = 109), and to public data (n = 1440), they demonstrate the ability of Ly6Ehi neutrophils to predict immunotherapy response in humans with high accuracy (average AUC ≈…
-
Molecular insights into atypical modes of β-arrestin interaction with seven transmembrane receptors
Investigators studied β-arrestins (βarrs), crucial proteins in seven transmembrane receptor (7TMR) signaling. Using cryo–electron microscopy, they captured seven structural states of βarrs, showcasing their interactions in basal, muscarinic receptor subtype 2 (M2R)-activated, and βarr-biased decoy D6 receptor (D6R)-activated states. These snapshots unveil unique βarr-7TMR engagements and reveal a structural shift in βarr2’s carboxyl terminus upon D6R activation. The findings provide unexpected molecular insights into 7TMR-βarr complexes, offering potential therapeutic avenues.
-
The energetic and allosteric landscape for KRAS inhibition
Despite numerous therapeutic protein targets being genetically-validated, the challenge remains in targeting proteins with elusive allosteric sites, especially those involved in protein-protein interactions. This study addresses the gap by mapping inhibitory allosteric communication in KRAS, a challenging target. The team quantifies the impact of mutations, unveiling allosteric sites and providing a roadmap for understanding and targeting proteins involved in critical cellular pathways. This approach promises rapid identification of allosteric target sites in various proteins.
-
Discovery of a structural class of antibiotics with explainable deep learning
Researchers urgently seek novel antibiotics amidst the ongoing antibiotic resistance crisis. This study introduces a deep learning-guided approach, combining machine learning and explainable graph algorithms, to explore chemical spaces for potential antibiotics. Testing over 12 million compounds, the team identified substructure-based rationales for antibiotic activity and low cytotoxicity. Empirical testing revealed a promising compound with selective activity against drug-resistant strains, demonstrating the potential of this approach in explaining and discovering new antibiotic structural classes.
-
A novel antibiotic class targeting the lipopolysaccharide transporter
Carbapenem-resistant Acinetobacter baumannii (CRAB) poses a global health threat, lacking effective treatments for over 50 years. Investigators have studied and introduces tethered macrocyclic peptide (MCP) antibiotics, specifically zosurabalpin (RG6006), demonstrating potent antibacterial activity against CRAB. The MCPs inhibit the LptB2FGC complex, impeding lipopolysaccharide transport and effectively treating drug-resistant CRAB isolates in vitro and in mouse models. This novel antibiotic class suggests a promising treatment for CRAB infections, addressing current inadequacies, and identifies LptB2FGC as a viable target for antimicrobial drug development.